Table 1.
Severity of clinical symptoms recorded in a daily symptom diary for 14 consecutive days by volunteers participating in the ENGORD and NSAID pilot studies
| Clinical symptom | Unit of measurement | ENGORD study
|
NSAID study
|
||||||
|---|---|---|---|---|---|---|---|---|---|
| Placebo (n=10) | Absorbatox™ (n=10) | P-value | Difference (%) | Placebo (n=11) | Absorbatox™ (n=11) | Difference (%) | P-value | ||
| Heartburn | Mean number of episodes per group ± SEM | 21.90±3.97 | 12.20±3.01a | P=0.03 | 44 | 5.46±3.51 | 3.01±2.11 | 40 | P=0.30 |
| Discomfort | Mean discomfort scores per group ± SEM | 2.53±0.40 | 1.17±0.28a | P=0.01 | 54 | 1.94±1.32 | 1.30±0.63 | 25 | P=0.33 |
| Pain | Mean pain scores per group ± SEM | 1.90±0.41 | 0.83±0.23a | P=0.04 | 56 | – | – | – | |
| Symptom-free days | Mean symptom-free days per group ± SEM | 2.60±0.93 | 4.4±1.03 | P=0.11 | 41 | – | – | – | |
Notes:
a
Significantly different when compared to the placebo group (P≤0.05). Absorbatox™ manufactured by Absorbatox (Pty) Ltd, Centurion, Gauteng, South Africa.
Abbreviations: ENGORD, endoscopically negative gastroesophageal reflux disease; NSAID, nonsteroidal anti-inflammatory drug; SEM, standard error of the mean.